Novartis completes $2.1bn acquisition of Endocyte to boost cancer treatment capabilities

Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its position as a leader in radiopharmaceuticals for ... Read More